Technical Analysis for ARCT - Arcturus Therapeutics Ltd.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 33.13 | -8.76% | -3.18 |
Earnings due: Mar 26
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 50 DMA | Bearish | 0.00% | |
MACD Bearish Centerline Cross | Bearish | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -8.76% | |
NR7 | Range Contraction | -8.76% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 22 hours ago |
Down 1 ATR | about 22 hours ago |
Down 5% | about 23 hours ago |
Fell Below Lower Bollinger Band | about 23 hours ago |
Lower Bollinger Band Support | about 23 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 03/26/2024
Arcturus Therapeutics Ltd. Description
Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine. MDX consists of a single bi-layer oral tablet, which includes both a rapid onset release metadoxine formulation and a slow release metadoxine formulation together providing the desired dual release profile. The new extended-release formulation prolongs the human plasma levels of metadoxine for up to 12 hours, which results in enhanced efficacy benefits. ADAIR is an oral, semi-solid, liquid-filled, hard gelatin capsule of an abuse-deterrent IR formulation of dextroamphetamine sulfate, which is manufactured as 10 mg capsules.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Health Sciences Drugs Pharmacology Euphoriants Amphetamine Cognitive Disorders Glutamate Tablet Adhd Taar1 Agonists
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 43.81 |
52 Week Low | 14.65 |
Average Volume | 420,284 |
200-Day Moving Average | 29.46 |
50-Day Moving Average | 35.96 |
20-Day Moving Average | 37.82 |
10-Day Moving Average | 36.97 |
Average True Range | 2.28 |
RSI (14) | 37.89 |
ADX | 17.88 |
+DI | 15.37 |
-DI | 29.48 |
Chandelier Exit (Long, 3 ATRs) | 36.96 |
Chandelier Exit (Short, 3 ATRs) | 39.87 |
Upper Bollinger Bands | 41.93 |
Lower Bollinger Band | 33.71 |
Percent B (%b) | -0.07 |
BandWidth | 21.74 |
MACD Line | -0.11 |
MACD Signal Line | 0.54 |
MACD Histogram | -0.6554 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 39.04 | ||||
Resistance 3 (R3) | 39.66 | 38.31 | 38.06 | ||
Resistance 2 (R2) | 38.31 | 36.80 | 38.00 | 37.73 | |
Resistance 1 (R1) | 35.72 | 35.88 | 35.05 | 35.10 | 37.40 |
Pivot Point | 34.37 | 34.37 | 34.03 | 34.06 | 34.37 |
Support 1 (S1) | 31.78 | 32.86 | 31.11 | 31.16 | 28.86 |
Support 2 (S2) | 30.43 | 31.94 | 30.12 | 28.53 | |
Support 3 (S3) | 27.84 | 30.43 | 28.21 | ||
Support 4 (S4) | 27.22 |